Sartorius and KMI Parexel agree on BioPharm-Alliance

Published: 2-Dec-2003


Sartorius North America and KMI Parexel International have now agreed to form an alliance that offers a comprehensive services and consulting portfolio to their customers in the biopharmaceutical industry. With this BioPharm-Alliance, the two companies intend to support pharmaceutical companies, particularly in their activities involving process development and optimisation, scale-up and commercial-scale drug production. In addition, the BioPharm-Alliance plans to provide consulting services to customers on effective regulatory compliance, especially with regard to validation, documentation and quality assurance. It is hoped that this new alliance will enable pharmaceutical companies to launch drugs more quickly and efficiently by integrating external expertise from the sectors of process development, scale-up and regulatory compliance. Reinhard Vogt, senior vice president of the Biotechnology Division at Sartorius welcomed the agreement, stating: "It is the right time for such an alliance as it addresses major needs of the biopharmaceutical industry in respect to time to market, compliance barriers and cost efficiencies."

T: +49(0)551 308 1686 petra.kirchhoff@sartorius.com www.sartorius.com

You may also like